✦ LIBER ✦

Hepatitis B and End-Stage Liver Disease

✍ Scribed by Weisberg, Ilan S.; Brown, Robert S.; Sigal, Samuel H.

Book ID: 122492745
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 334 KB
Volume: 11
Category: Article
ISSN: 1089-3261
DOI: 10.1016/j.cld.2007.08.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pretransplantation interferon treatment

Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B–related end-stage liver disease

✍ Patrick Marcellin; Didier Samuel; Jorge Areias; Marie-Anne Loriot; Jean-Louis Ar 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 603 KB

Orthotopic liver transplantation in patients with hepatitis B-related cirrhosis is commonly complicated by reinfection with the hepatitis B virus, with rapidly progressive liver disease and poor survival rate. We assessed the efficacy of prior therapy with recombinant interferon-a on the prevention

Double-dose accelerated hepatitis B vacc

Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease

✍ Mehmet Arslan; Russell H. Wiesner; Corey Sievers; Kathleen Egan; Nizar N. Zein 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

End-stage liver disease and liver transp

End-stage liver disease and liver transplantation: Role of lamivudine therapy in patients with chronic hepatitis B

✍ Emmet B. Keeffe 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 2 views

Prophylaxis against hepatitis B virus re

Prophylaxis against hepatitis B virus recurrence after liver transplantation for hepatitis B virus-related end-stage liver diseases with severe hypersplenism and splenomegaly: Role of splenectomy

✍ Yu Zhang; Lunan Yan; Tianfu Wen; Bo Li; Jichun Zhao; Zheyu Chen; Wentao Wang; Mi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 788 KB

Protective antibody levels and dose requ

Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease

✍ Rolland C. Dickson; Norah A. Terrault; Michael Ishitani; K. Rajender Reddy; Patr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 1 views

Lamivudine combined with Hepatitis B immune globulin (HBIg) prevents post liver transplant (LT) HBV recurrence. The study was designed to assess the impact of lamivudine on hepatitis B antibody (anti-HBs) and dosage requirements of intravenous 5% HBIg (Nabi-HB) in the first 36 weeks post LT. Adults

Accumulation and persistence of hepatiti

Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease

✍ S Günther; S Baginski; H Kissel; P Reinke; D H Krüger; H Will; H Meisel 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 658 KB

Evidence is accumulating that HBV variants may influence In renal transplant recipients, chronic hepatitis B vithe clinical course of hepatitis B. For instance, HBV with rus (HBV) infection often leads to cirrhosis and liver a point mutation in the preC-region (preC-variant), which failure. In this